Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Sensei Biotherapeutics ( (SNSE) ).
On May 21, 2025, Sensei Biotherapeutics held its annual meeting of stockholders, where three proposals were considered. The stockholders elected two nominees to the Board of Directors, ratified the appointment of Deloitte & Touche LLP as the independent public accounting firm for 2025, and approved an amendment for a reverse stock split of common stock.
The most recent analyst rating on (SNSE) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Sensei Biotherapeutics stock, see the SNSE Stock Forecast page.
Spark’s Take on SNSE Stock
According to Spark, TipRanks’ AI Analyst, SNSE is a Underperform.
Sensei Biotherapeutics faces substantial financial challenges, with no revenue and ongoing net losses. The technical analysis indicates a bearish trend, and the valuation is poor due to negative earnings. However, the positive corporate event regarding trial results offers a glimpse of potential future success. The overall score reflects these mixed factors, with financial weaknesses being the most significant deterrent.
To see Spark’s full report on SNSE stock, click here.
More about Sensei Biotherapeutics
Sensei Biotherapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative immunotherapies for cancer treatment.
Average Trading Volume: 2,712,065
Technical Sentiment Signal: Sell
Current Market Cap: $7.55M
Learn more about SNSE stock on TipRanks’ Stock Analysis page.